Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired ...

IVI RMA North America, a leader in fertility care and assisted reproduction, will deliver 36 presentations and poster ...

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets ...

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and ...

(per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in patients with tumors harboring mutations ...

Orna Therapeutics, a leading biotechnology company developing a proprietary pipeline of in vivo therapies across a broad range of autoimmune and oncology indications, today announced an upcoming ...

Reviving Parampara for a United World', will be held between 20 and 22 November at Adani Shantigram Township in Ahmedabad.

The Pakistan Advanced Materials Forum (PAMF) has announced that the 19th International Symposium on Advanced Materials (ISAM-2025) ...

Jacobio Pharma (1167.HK) announced that it presented the pre-clinical data of its internally discovered pan-KRAS inhibitor JAB-23E73 in a poster presentation at the 2025 AACR-NCI-EORTC International ...